Structure Therapeutics Inc (GPCR)

$64.70 +1.93 (3.07%)
Market Cap 4.13B
Revenue (ttm) 0.00
Net Income (ttm) -122.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,003,486
Avg Vol 1,633,942
Day's Range N/A - N/A
Shares Out 60.68M
Stochastic %K 9%
Beta -2.05
Analysts Strong Sell
Price Target $99.43

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
S_Franconi
S_Franconi Jan. 6 at 7:45 PM
$GPCR There are too many $VKTX spammers on this board. Go back to $VKTX where you belong. Spam yourselves.
1 · Reply
Quantumup
Quantumup Jan. 6 at 10:55 AM
BMO Capital reiterated $GPCR Outperform-$130 and said, Licensing agreement with Genentech is not the large Pharma partnership that some Structure owners have been anxiously awaiting. $RHHBY $VKTX $NVO $LLY AMGN PFE BMO Capital went on to say: https://x.com/Quantumup1/status/2008491388048920644?s=20
0 · Reply
JonathanV
JonathanV Jan. 5 at 11:26 PM
$GPCR so they sold some IP to Roche for $100 million. Random
0 · Reply
blocktrade
blocktrade Jan. 5 at 10:27 PM
$GPCR Guy Adami pumping on fast money. Thinks they will get bought out before the end of the year.
0 · Reply
warrants_Moon
warrants_Moon Jan. 5 at 8:14 PM
$ALT $GPCR $LLY $NVO $VKTX OINK OINK piggy! 🐷
2 · Reply
cubie
cubie Jan. 5 at 4:19 PM
$LLY $NVO forgot include retail fav $VKTX to poot party bc nvo. $GPCR too , why $ALT up tho🤔😅
0 · Reply
himsssss
himsssss Jan. 5 at 3:11 PM
$VKTX $GPCR The left over companies are going to be undersold by Chinese Biotechs if they don't hurry and plan to sell soon. Keep your eyes on Ascletis ($400M valuation last year to now $1.6B), next buyout/partner target by the BP. If these guys taken out for cheap, it won't be good for the rest. "ASC30 is designed for once-daily oral dosing as well as once-monthly to once-quarterly subcutaneous administration for diabetes, obesity, and other metabolic diseases." https://www.clinicaltrialsarena.com/news/ascletis-fda-approval-asc30/?cf-view
0 · Reply
blocktrade
blocktrade Jan. 5 at 6:15 AM
$GPCR 🤔
0 · Reply
blocktrade
blocktrade Jan. 5 at 4:59 AM
$GPCR
0 · Reply
biolover
biolover Jan. 3 at 2:57 PM
$VKTX look at 2025 q3 vs q2 big institutions ownership. If it were not FMR sale to save the shorts post data , Vk could have been $60 by now just from coverage. They reached 32% SI . . Most institutions actually increased positions post Aug data. most noted JPM by 95% or 2.5 M shares. This is very positive as I am sure JPM communicates with their health unit with such large acquisition and thus placed Viking with the best biotechs on meeting Monday schedule .. FMR sold Vk at $25 and it is the one lifted $GPCR from pre market drop post data and caused squeeze . I will remind you when $LLY starts reporting G4 ALT elevation in q2 q3 and what would happen to this FMR move.
2 · Reply
Latest News on GPCR
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 26 days ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 27 days ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Dec 9, 2025, 8:30 AM EST - 4 weeks ago

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Dec 8, 2025, 7:27 PM EST - 4 weeks ago

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Dec 8, 2025, 5:18 PM EST - 4 weeks ago

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 4 weeks ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Dec 8, 2025, 12:46 PM EST - 4 weeks ago

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 4 weeks ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 4 weeks ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 4 weeks ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 4 weeks ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 2 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 2 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 2 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 1:54 PM EDT - 4 months ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 5 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 7 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 7 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Apr 14, 2025, 10:49 AM EDT - 9 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 10 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 10 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 10 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Mar 20, 2025, 9:28 AM EDT - 10 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Jan 6, 2025, 2:53 PM EST - 1 year ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 1 year ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 1 year ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 4:05 PM EST - 1 year ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Mar 8, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Jan 17, 2024, 3:40 PM EST - 2 years ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX TERN

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Dec 20, 2023, 11:17 AM EST - 2 years ago

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

LLY NVO ALT AMGN VKTX

S_Franconi
S_Franconi Jan. 6 at 7:45 PM
$GPCR There are too many $VKTX spammers on this board. Go back to $VKTX where you belong. Spam yourselves.
1 · Reply
Quantumup
Quantumup Jan. 6 at 10:55 AM
BMO Capital reiterated $GPCR Outperform-$130 and said, Licensing agreement with Genentech is not the large Pharma partnership that some Structure owners have been anxiously awaiting. $RHHBY $VKTX $NVO $LLY AMGN PFE BMO Capital went on to say: https://x.com/Quantumup1/status/2008491388048920644?s=20
0 · Reply
JonathanV
JonathanV Jan. 5 at 11:26 PM
$GPCR so they sold some IP to Roche for $100 million. Random
0 · Reply
blocktrade
blocktrade Jan. 5 at 10:27 PM
$GPCR Guy Adami pumping on fast money. Thinks they will get bought out before the end of the year.
0 · Reply
warrants_Moon
warrants_Moon Jan. 5 at 8:14 PM
$ALT $GPCR $LLY $NVO $VKTX OINK OINK piggy! 🐷
2 · Reply
cubie
cubie Jan. 5 at 4:19 PM
$LLY $NVO forgot include retail fav $VKTX to poot party bc nvo. $GPCR too , why $ALT up tho🤔😅
0 · Reply
himsssss
himsssss Jan. 5 at 3:11 PM
$VKTX $GPCR The left over companies are going to be undersold by Chinese Biotechs if they don't hurry and plan to sell soon. Keep your eyes on Ascletis ($400M valuation last year to now $1.6B), next buyout/partner target by the BP. If these guys taken out for cheap, it won't be good for the rest. "ASC30 is designed for once-daily oral dosing as well as once-monthly to once-quarterly subcutaneous administration for diabetes, obesity, and other metabolic diseases." https://www.clinicaltrialsarena.com/news/ascletis-fda-approval-asc30/?cf-view
0 · Reply
blocktrade
blocktrade Jan. 5 at 6:15 AM
$GPCR 🤔
0 · Reply
blocktrade
blocktrade Jan. 5 at 4:59 AM
$GPCR
0 · Reply
biolover
biolover Jan. 3 at 2:57 PM
$VKTX look at 2025 q3 vs q2 big institutions ownership. If it were not FMR sale to save the shorts post data , Vk could have been $60 by now just from coverage. They reached 32% SI . . Most institutions actually increased positions post Aug data. most noted JPM by 95% or 2.5 M shares. This is very positive as I am sure JPM communicates with their health unit with such large acquisition and thus placed Viking with the best biotechs on meeting Monday schedule .. FMR sold Vk at $25 and it is the one lifted $GPCR from pre market drop post data and caused squeeze . I will remind you when $LLY starts reporting G4 ALT elevation in q2 q3 and what would happen to this FMR move.
2 · Reply
Kartoffeln
Kartoffeln Jan. 2 at 3:01 PM
$GPCR lower today than it was in late 2023, now with more mature data. Not sure what that means going forward 🤷‍♂️
1 · Reply
bavariaron
bavariaron Jan. 1 at 3:57 PM
$GPCR Yes — Jared Holz on CNBC looking at GPCR (NP) as next likely M&A event. https://youtu.be/Dqt_9iKsvD4?si=ZCtGI9SoG4w-ge40
2 · Reply
The1Albatross
The1Albatross Jan. 1 at 12:59 AM
$GPCR Bring it
1 · Reply
blocktrade
blocktrade Dec. 31 at 10:12 PM
$GPCR what was that nonsense after hours? Did someone mention it on cnbc?
0 · Reply
JonathanV
JonathanV Dec. 31 at 9:43 PM
$GPCR you go ahead and pull those panties to the side, Ray, and you take $15 billion for the company
1 · Reply
JonathanV
JonathanV Dec. 31 at 9:39 PM
$GPCR odds we’re bought circa JP Morgan? I’d say at least 50%
0 · Reply
S_Franconi
S_Franconi Dec. 31 at 9:38 PM
$GPCR Nice.
0 · Reply
himsssss
himsssss Dec. 30 at 6:51 PM
$VKTX Stop the nonsense, its not at this price level because this ticker is manipulated by shorts or funds. I've been blocked for calling things as is and have been right about it this whole time. No BP is going to buyout this out of date pipeline with thin data. Oral pill went from hype to dull real quick after p2 data. Companies that didn't cut corners, and kept working have now caught up or went past this ticker. $GPCR being valued about $1B more isn't because of manipulation. $MTSR being bought out at $10B while VKTX struggles to hold $4B isnt because of poor choices by BP.
3 · Reply
keylimepie2
keylimepie2 Dec. 30 at 12:17 AM
$VKTX $GPCR $NVO $LLY $PFE Courtesy reminder for all who believe the anti-trust “experts” claiming $NVO or $LLY acquiring $VKTX would raise FTC concerns have no clue what they’re talking about. Don’t fall for their paper thin, over-reaching nonsense claims. https://www.biospace.com/business/delaware-court-denies-pfizers-bid-to-block-novo-metsera-deal#:~:text=The%2520court&%2339;s%2520decision%2520allows%2520Metsera,from%2520Pfizer%2520for%2520$8.5%2520billion
2 · Reply
biolover
biolover Dec. 28 at 5:05 PM
$VKTX FDA CRL to $SNY Tolebrubtinib is all about DILI Table below is not much worse than $LLY reported with orforglipron , and recall $GPCR only had small sample? Adjudication of ALT elevation cause is not easy and the FDA digs deep. Don’t expect FDA to give free pass to Lilly on this ? If someone ever dies due to DILI , FDA takes full ethical responsibility. Particularly for drugs that have better alternatives.
1 · Reply
CoManagerC
CoManagerC Dec. 27 at 9:09 AM
$GPCR The backdrop favors measured delivery over aggressive expansion promises. Operational cadence needs to tighten meaningfully. Transparency improvements could narrow valuation spreads. Sentiment should follow confirmed results rather than headlines.
1 · Reply
CattleFarmerJ
CattleFarmerJ Dec. 27 at 4:18 AM
$GPCR got 3600 shares at 19 so im just going to wait for at least my 1 year and 1 day to sell for long term gain i think 140 is on the table next year with good Earning forecast and guidance for the time table.
1 · Reply